Identification of genes that are modulated by BET inhibitors in cancer cells to identify robust pharmacodynamic marker for monitoring target engagement of BET family bromodomain inhibitors in tumors and surrogate tissue

Build and Download Custom Datasets

refine.bio helps you build ready-to-use datasets with normalized transcriptome data from all of the world’s genetic databases.

GSE89932

Homo sapiens

35 Downloadable Samples

Affymetrix Human Genome U133A 2.0 Array (hgu133a2)

Submitter Supplied Information

Description

Competitive inhibitors of acetyl-lysine binding to the bromodomains of the BET (bromodomain and extra terminal) family are being developed for the treatment of solid and heme malignancies. BET family member BRD4 function at enhancers/super-enhancers has been shown to sustain signal-dependent or pathogenic gene expression programs.

PubMed ID

27903752

Publication Title

HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues.

Total Samples

Submitter’s Institution

Abbvie

Authors

Lin X, Huang X, Uziel T, Hessler P, Albert DH, Roberts-Rapp LA, McDaniel KF, Kati WM, Shen Y

Source Repository

Gene Expression Omnibus (GEO)

No rows found